Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has maintained an 'Outperform' rating and a $65 price target for Jasper Therapeutics (NASDAQ:JSPR), as stated by analyst Gavin Clark-Gartner.
August 26, 2024 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group has reaffirmed its 'Outperform' rating and $65 price target for Jasper Therapeutics, indicating confidence in the company's future performance.
The reaffirmation of an 'Outperform' rating and a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100